LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare diseases. He most recently served as Vice President, Head of Neuromuscular Development Unit at Biogen, Inc. "Voyager is advancing rapidly toward the clinic, with one IND filing targeted each year through